Targeting TYK2 for Fighting Diseases: Recent Advance of TYK2 Inhibitors

Area of Science:

• Biochemistry and Molecular Biology
• Immunology
• Medicinal Chemistry

Background:

• Tyrosine-protein kinase 2 (TYK2) is a Janus kinase (JAK) family member involved in immune signaling pathways.
• Dysregulated TYK2 activity is implicated in autoimmune diseases including psoriasis, inflammatory bowel disease, and systemic lupus erythematosus.
• TYK2 mediates signal transduction for cytokines like IL-12, IL-23, and IL-10, influencing immune responses.

Purpose of the Study:

• To provide a comprehensive overview of TYK2 inhibitors.
• To discuss the protein structure, signaling pathways, synthesis, structure-activity relationships, and clinical research of TYK2 inhibitors.

Main Methods:

• Review of existing literature on TYK2 and its inhibitors.
• Classification of TYK2 inhibitors based on binding sites (JH2 allosteric vs. JH1 ATP-competitive).
• Discussion of representative inhibitors, such as BMS-986165.

Main Results:

• TYK2 inhibitors can effectively block excessive immune signaling, offering therapeutic potential.
• Two main classes of TYK2 inhibitors exist: allosteric inhibitors targeting JH2 and ATP-competitive inhibitors targeting JH1.
• BMS-986165 is a notable example of an allosteric TYK2 inhibitor.

Conclusions:

• TYK2 inhibitors represent a promising therapeutic strategy for various immune-mediated diseases.
• Understanding the structure, mechanism, and clinical profile of these inhibitors is crucial for drug development.